Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Golden Cariboo (CSE:GCC) (OTC:GCCFF) Expands Gold Footprint in BC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News ARS Pharmaceuticals Inc SPRY

Healthcare Biotechnology
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.... see more

Current News (NDAQ:SPRY)

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

GlobeNewswire 6 days ago

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg

GlobeNewswire February 2, 2026

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

GlobeNewswire January 21, 2026

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

GlobeNewswire December 29, 2025

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire November 26, 2025

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

GlobeNewswire November 10, 2025

ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)

GlobeNewswire November 4, 2025

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

GlobeNewswire November 3, 2025

ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

GlobeNewswire November 3, 2025
View More News ››

Opinion & Analysis (NDAQ:SPRY)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SPRY)

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Navigating the Intr

http://beyondspx.com/2024/08/02/ars-pharmaceuticals-inc-nasdaqspry-navigating-the-intranasal-epinephrine-landscape/
MikeTester - August 3, 2024
View more Bullboard ››

Calima Energy Ltd (EM)

Calima Energy Ltd (EM)

Calima Energy Limited invests in oil and gas exploration and production projects in Canada and internationally. The company ...
View More »

Podcasts